Price Relief, Innovation, and Competition for Essential Drugs Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jul 26, 2018)
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.
This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
What just happenedJul 27, 2018
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseJul 26, 2018
- Jul 27, 2018Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jul 26, 2018IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Jul 26, 2018IntroReferralIntro-H
Introduced in House
- Jul 26, 2018IntroReferral1000
Introduced in House